ReviewAdvanced drug delivery reviews2020
Polymer nanomedicines.
Review in Advanced drug delivery reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 125 citations in OpenAlex.
- Multifunctional CMC-Nanographene Oxide Hydrogels Couple Fluorophore-Free Cancer Cell Imaging with Antioxidant and Antimicrobial Activity.Pharmaceutics · 2026Article
- A γ-Ray-Responsive Dynamic Covalent Polymeric Radioprotectant for Efficient Radiation Injury Treatment.Advanced healthcare materials · 2026Article
- Nanodrug delivery systems enhance traditional Chinese medicine treatment of osteoporosis.Discover nano · 2026Review
- From single DNA molecule to nanoparticle formation: mechanistic basis for monocationic aromatic drug-induced DNA frameworks.Journal of nanobiotechnology · 2026Article
- From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics.International journal of molecular sciences · 2026Review
- Synthesis, Supramolecular Assembly, and Hydrogelation of Poly(amino ester) ABA Triblock Copolymers.Biomacromolecules · 2026Article
- Nanomedicines for Delivery of Cytarabine: Effect of Carrier Structure and Spacer on the Anti-Lymphoma Efficacy.Polymers · 2025Article
- Polymer Nanomedicines with pH-Triggered Pirarubicin Release: Revealing the Role of Carrier Hydrophilicity and Release Kinetics in Anticancer Performance.Biomacromolecules · 2025Article
- Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy.Pharmaceutics · 2025Review
- Review
- Review
- PD-L1 targeted antibody-polymer-Epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Synthesis and Characterization of Polymer-Drug Conjugates by Strain-Promoted Azide-Alkyne Cycloaddition-Mediated Polymerization.Journal of applied polymer science · 2025Article
- Blood-brain barrier crossing biopolymer targeting c-Myc and anti-PD-1 activate primary brain lymphoma immunity: Artificial intelligence analysis.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Emerging synergistic strategies for enhanced antibacterial sonodynamic therapy: Advances and prospects.Ultrasonics sonochemistry · 2025Review
- Machine Learning-Driven Prediction, Preparation, and Evaluation of Functional Nanomedicines Via Drug-Drug Self-Assembly.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Synthesis of polymer-clindamycin conjugates through lipase-catalyzed esterification and RAFT polymerization.Polymer · 2025Article
- Review
- Hot-spot empowered gold nanoparticles for theranostics in breast cancer.Theranostics · 2025Review
- Guanidine-Derived Polymeric Nanoinhibitors Target the Lysosomal V-ATPase and Activate AMPK Pathway to Ameliorate Liver Lipid Accumulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Polymer nanomedicines (macromolecular therapeutics, polymer-drug conjugates, drug-free macromolecular therapeutics) are a group of biologically active compounds that are characterized by their large molecular weight. This review focuses on bioconjugates of water-soluble macromolecules with low molecular weight drugs and selected proteins. After analyzing the design principles, different structures of polymer carriers are discussed followed by the examination of the efficacy of the conjugates in animal models and challenges for their translation into the clinic. Two innovative directions in macromolecular therapeutics that depend on receptor crosslinking are highlighted: a) Combination chemotherapy of backbone degradable polymer-drug conjugates with immune checkpoint blockade by multivalent polymer peptide antagonists; and b) Drug-free macromolecular therapeutics, a new paradigm in drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.